Health Care [ 4/12 ] | Pharmaceuticals [ 9/75 ]
NASDAQ | Common Stock
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 26 | 0.01 Decreased by -5.04% | 0.04 Decreased by -64.61% |
| Nov 5, 25 | -0.24 Decreased by -50.00% | -0.15 Decreased by -60.00% |
| Aug 5, 25 | -0.27 Decreased by -575.00% | -0.10 Decreased by -170.00% |
| May 5, 25 | -0.17 Decreased by -88.89% | -0.10 Decreased by -70.00% |
| Mar 4, 25 | 0.01 Increased by +111.58% | 0.02 Decreased by -37.67% |
| Nov 6, 24 | -0.16 Increased by 0.00% | -0.10 Decreased by -60.00% |
| Jul 31, 24 | -0.04 Increased by +78.95% | -0.05 Increased by +20.00% |
| May 7, 24 | -0.09 Increased by +40.00% | -0.10 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 90.30 M Increased by +14.38% | 130.00 K Increased by +101.91% | Increased by +0.14% Increased by +101.67% |
| Sep 30, 25 | 68.97 M Increased by +12.90% | -15.74 M Increased by +17.91% | Decreased by -22.82% Increased by +27.29% |
| Jun 30, 25 | 69.39 M Increased by +3.70% | -17.14 M Decreased by -51.03% | Decreased by -24.70% Decreased by -45.64% |
| Mar 31, 25 | 68.52 M Increased by +15.49% | -18.89 M Decreased by -44.11% | Decreased by -27.57% Decreased by -24.79% |
| Dec 31, 24 | 78.95 M Increased by +29.42% | -6.79 M Increased by +42.60% | Decreased by -8.60% Increased by +55.65% |
| Sep 30, 24 | 61.09 M Increased by +22.12% | -19.17 M Decreased by -13.28% | Decreased by -31.38% Increased by +7.24% |
| Jun 30, 24 | 66.91 M Increased by +35.59% | -11.35 M Increased by +37.43% | Decreased by -16.96% Increased by +53.85% |
| Mar 31, 24 | 59.33 M Increased by +42.21% | -13.11 M Increased by +11.37% | Decreased by -22.09% Increased by +37.68% |